ArticleJournal of surgical oncology2026
Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesWhile tranexamic acid (TXA) reduces blood loss in orthopedic surgery, thromboembolic concerns in cancer patients have limited adoption in orthopedic oncology. This study evaluated TXA efficacy and safety in patients undergoing endoprosthetic reconstruction for oncologic indications.
methodsThis retrospective single-center study included 617 patients who underwent lower extremity endoprosthetic reconstruction for oncologic indications between 2000 and 2024. Patients were stratified by perioperative TXA administration (n = 166) versus no TXA (n = 451). The primary outcome was perioperative blood loss calculated using the Mercuriali method. Secondary outcomes included perioperative packed red blood cells (pRBC) transfusion, hospital length of stay, and 90-day venous thromboembolic (VTE) complications.
resultsTXA was associated with a 429 mL reduction in calculated perioperative blood loss (1878 ± 1168 mL vs. 2307 ± 1442 mL; p = 0.003). TXA was not associated with reduced intraoperative pRBC transfusion rates (31% vs. 33%; RR 0.96 [95% CI: 0.74-1.25], p = 0.752) but was associated with significantly reduced postoperative transfusion requirements (17% vs. 30%; RR 0.56 [95% CI: 0.39-0.81], p = 0.003). No significant differences existed in 90-day VTE complications, reoperation rates, or mortality.
conclusionsPerioperative TXA use was associated with reduced blood loss and postoperative transfusion requirements without a detectable increase in thromboembolic complications, supporting TXA as a beneficial adjunct in musculoskeletal oncology limb salvage procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.